Supply of pimecrolimus (Elidel) 1% w/w cream by Meda Pharmaceuticals Pty Ltd

Overview

The Therapeutic Goods Act 1989 (TGA) was enacted to regulate the supply and use of therapeutic goods in Australia, ensuring that these goods are of acceptable quality, safety, and efficacy. This Act addresses the problem of ensuring that therapeutic goods are correctly labelled and supplied according to established standards. The Act was enacted by the Commonwealth Parliament and its policy objective is to protect public health by regulating the therapeutic goods market. On July 24, 2012, the delegate of the Secretary of the Department of Health and Ageing granted consent for the supply of pimecrolimus (Elidel) 1% w/w cream, which did not conform to certain labelling requirements as per Therapeutic Goods Order 69. This consent, which is subject to specific conditions such as the use of existing labels and arrangements for handling complaints, is aimed at ensuring that the product remains available to the public under controlled conditions until the end of February 2013.

Scope and Application

The Therapeutic Goods Act 1989, as amended by Section 14 and 14A Notice, applies specifically to the supply of therapeutic goods within Australia. In this instance, the Act has been invoked to permit the supply of pimecrolimus (Elidel) 1% w/w cream by Meda Pharmaceuticals Pty Ltd, despite the product not fully conforming with certain labelling requirements as stipulated in the Therapeutic Goods Order 69. The consent given by the delegate of the Secretary of the Department of Health and Ageing is tailored to this particular situation, allowing the product to be supplied with labels that still bear the details of the previous sponsor, Novartis Pharmaceuticals Australia Pty Ltd, until the end of February 2013. This consent ensures that the product can continue to be supplied without interruption, while also placing specific conditions on its labelling and complaint handling arrangements to ensure consumer safety and regulatory compliance. This application of the Act demonstrates its flexibility in accommodating specific situations while maintaining the overarching goal of protecting public health through stringent control over therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, specifically referencing sections 14 and 14A, outlines the legislative framework under which the supply of therapeutic goods is permitted under certain conditions. In this instance, the delegate of the Secretary of the Department of Health and Ageing has consented to the supply of pimecrolimus (Elidel) 1% w/w cream by Meda Pharmaceuticals Pty Ltd, despite the product not fully conforming to the Therapeutic Goods Order 69. The non-conformity pertains to the product labels, which still list the details of the previous sponsor, Novartis Pharmaceuticals Australia Pty Ltd, instead of the current sponsor, Meda Pharmaceuticals Pty Ltd. This consent, granted under subsection 15(1) of the Act, is valid until the end of February 2013 for both 15 g and 30 g presentations of the product. Under the terms of this consent, the product will continue to be supplied with the existing labels, which are those previously used by Novartis Pharmaceuticals Australia Pty Ltd. Importantly, no other changes to the product have been made without the approval of the Therapeutic Goods Administration (TGA). This restriction ensures that any alterations to the product must be vetted and approved by the TGA to maintain compliance with therapeutic goods standards. Additionally, the Act stipulates that there must be arrangements in place to promptly forward any complaints or queries regarding the product to Meda Pharmaceuticals Pty Ltd. The Therapeutic Goods Act 1989 imposes several obligations on the parties involved in the supply of therapeutic goods. Meda Pharmaceuticals Pty Ltd, as the new sponsor, must ensure that the product complies with all relevant regulations and standards. This includes maintaining records of any changes to the product, particularly those that impact the labelling. The company must also ensure that any complaints or queries are handled efficiently and that they are directed to the appropriate department within the organisation. Furthermore, the TGA retains the authority to inspect and verify compliance with the conditions of the consent. Failure to adhere to the conditions set out in the consent or to the requirements of the Therapeutic Goods Act 1989 may result in various consequences. The Act provides for both civil and criminal penalties for breaches, which can include fines and imprisonment. The specific penalties are determined based on the nature and severity of the breach. For instance, supplying non-compliant therapeutic goods can result in substantial fines, with the exact amount dependent on the seriousness of the non-compliance. In more severe cases, individuals or entities found guilty of criminal offences under the Act may face imprisonment, underscoring the importance of strict adherence to the legislative requirements.